Study #2020-0271
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
MD Anderson Study Status
Not Accepting
Treatment Agent
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Description
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
Study phase:
Phase II
Physician name:
Jonathan Gill
Department:
Neuro-Oncology
For general questions about clinical trials:
1-833-644-2296
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.